- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07653685
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: Ruihua Xu, Doctor
- Telefonní číslo: 020-87343468
- E-mail: xurh@syscc.org.cn
Studijní místa
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100034
- Zatím nenabíráme
- Peking University First Hospital
-
Kontakt:
- Shikai Wu, Doctor
- Telefonní číslo: 15810037307
- E-mail: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Čína, 400016
- Zatím nenabíráme
- The First Affiliated Hospital of Chongqing Medical University
-
Kontakt:
- Tao Zhang, Doctor
- Telefonní číslo: 13708311156
- E-mail: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, Čína, 730050
- Zatím nenabíráme
- Gansu Provincial Tumor Hospital
-
Kontakt:
- Zhihu Li, Master
- Telefonní číslo: 18993042850
- E-mail: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, Čína, 528000
- Zatím nenabíráme
- The First People's Hospital of Foshan
-
Kontakt:
- Wei Wang, Doctor
- Telefonní číslo: 18038863618
- E-mail: wangwei@fsyyy.com
-
Guangzhou, Guangdong, Čína, 510060
- Nábor
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Ruihua Xu, Doctor
- Telefonní číslo: 020-87343468
- E-mail: xurh@syscc.org.cn
-
Guangzhou, Guangdong, Čína, 510000
- Zatím nenabíráme
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Kontakt:
- Yanhon Den, Doctor
- Telefonní číslo: 13925106525
- E-mail: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, Čína, 530000
- Zatím nenabíráme
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Kontakt:
- Rong Liang, Doctor
- Telefonní číslo: 18677070811
- E-mail: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, Čína, 563000
- Nábor
- The Affiliated Hospital of Zunyi Medical University
-
Kontakt:
- Jiwei Wang, Doctor
- Telefonní číslo: 18013964231
- E-mail: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, Čína, 150000
- Zatím nenabíráme
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Tongsen Zheng, Doctor
- Telefonní číslo: 15134569619
- E-mail: zhengtongsen@126.com
-
Kontakt:
- Yuxian Bai, Doctor
- Telefonní číslo: 13945095085
- E-mail: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, Čína, 161005
- Zatím nenabíráme
- Qiqihar First Hospital
-
Kontakt:
- Xiyuan Sun, Doctor
- Telefonní číslo: 13945258792
- E-mail: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, Čína, 450000
- Zatím nenabíráme
- Henan Cancer Hospital
-
Kontakt:
- Ying Liu, Doctor
- Telefonní číslo: 13783604602
- E-mail: yaya7207@126.com
-
Zhengzhou, Henan, Čína, 450000
- Zatím nenabíráme
- The Third People's Hospital of Zhengzhou
-
Kontakt:
- HaiCun Wang, Master
- Telefonní číslo: 13803833783
- E-mail: whc1975@126.com
-
Zhengzhou, Henan, Čína, 450000
- Zatím nenabíráme
- The first affiliated hospital of Zhengzhou university
-
Kontakt:
- Yongxu Jia, Doctor
- Telefonní číslo: 15237128281
- E-mail: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, Čína, 434099
- Zatím nenabíráme
- Jingzhou First People's Hospital
-
Kontakt:
- Yan Hu, Master
- Telefonní číslo: 18163137369
- E-mail: helensparkle@163.com
-
Wuhan, Hubei, Čína, 430022
- Zatím nenabíráme
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Hongli Liu, Doctor
- Telefonní číslo: 13995680822
- E-mail: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, Čína, 410013
- Nábor
- Hunan Cancer Hospital
-
Kontakt:
- Yi He, Doctor
- Telefonní číslo: 18692237222
- E-mail: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210008
- Nábor
- Nanjing Drum Tower Hospital
-
Kontakt:
- Yudong Qiu, Doctor
- Telefonní číslo: 13951806490
- E-mail: yudongqiu510@163.com
-
Nanjing, Jiangsu, Čína, 210009
- Nábor
- Zhongda Hospital Southeast University
-
Kontakt:
- CaiLian Wang, Doctor
- Telefonní číslo: 13851756378
- E-mail: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, Čína, 210000
- Zatím nenabíráme
- Jiangsu Provincial Cancer Hospital
-
Kontakt:
- Yuanhua Liu, Doctor
- Telefonní číslo: 13305180356
- E-mail: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Čína, 330000
- Zatím nenabíráme
- Jiangxi Provincal People's Hospital
-
Kontakt:
- Weirong Yao, Doctor
- Telefonní číslo: 13907002901
- E-mail: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, Čína, 130021
- Zatím nenabíráme
- Jilin Cancer Hospital
-
Kontakt:
- Hongxia Cui, Master
- Telefonní číslo: 13504436090
- E-mail: 2503074283@qq.com
-
Changchun, Jilin, Čína, 130021
- Zatím nenabíráme
- The first hospital of Jilin University
-
Kontakt:
- Tingting Liang, Doctor
- Telefonní číslo: 15804303776
- E-mail: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, Čína, 110000
- Nábor
- Liaoning Cancer Hospital & Institute
-
Kontakt:
- Jingdong Zhang, Doctor
- Telefonní číslo: 18040007878
- E-mail: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Čína, 710000
- Zatím nenabíráme
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Kontakt:
- Aili Suo, Doctor
- Telefonní číslo: 18991232561
- E-mail: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína, 200127
- Nábor
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Kontakt:
- XiuYing Xiao, Doctor
- Telefonní číslo: 13564579313
- E-mail: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, Čína, 710000
- Zatím nenabíráme
- The Second Affiliated Hospital of Air Force Medical University
-
Kontakt:
- Haichuan Su, Doctor
- Telefonní číslo: 18629190366
- E-mail: cntdgcp@163.com
-
Xi’an, Shanxi, Čína, 710000
- Zatím nenabíráme
- The First Affiliated Hospital of Air Force Medical University
-
Kontakt:
- Yongzhan Nie, Doctor
- Telefonní číslo: 15091520001
- E-mail: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Čína, 300202
- Nábor
- Tianjin Medical University Cancer Institute & Hospital
-
Kontakt:
- Zhanyu Pan, Master
- Telefonní číslo: 18622221256
- E-mail: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, Čína, 300121
- Zatím nenabíráme
- Tianjin Union Medical Center
-
Kontakt:
- Mingqing Zhang, Doctor
- Telefonní číslo: 15122875158
- E-mail: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, Čína, 830054
- Zatím nenabíráme
- Xinjiang Medical University Affiliated Tumor Hospital
-
Kontakt:
- YanLi Qu, Master
- Telefonní číslo: 18160627963
- E-mail: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, Čína, 323000
- Nábor
- Lishui Municipal Central Hospital
-
Kontakt:
- Yanru Xie, Master
- Telefonní číslo: 13567615770
- E-mail: 43437677@qq.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Aktivní komparátor: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Recommended Phase 2 Dose
Časové okno: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Časové okno: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Časové okno: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Half-life
Časové okno: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Časové okno: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Časové okno: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Časové okno: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Časové okno: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Časové okno: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Časové okno: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Časové okno: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Časové okno: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Časové okno: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- TQB2930-Ib/II-02
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .